BIO
NEUTRAL
$296.57
Live
Bio-Rad Laboratories, Inc. · NYSE
Target $348.0
(+17.3%)
$211.43
52W Range
$373.69
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$8.0B
P/E
N/A
ROE
-9.5%
Profit margin
-26.4%
Debt/Equity
0.21
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
72%
Bio-Rad Laboratories has a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score for distress risk assessment. The company shows strong gross margins and solid earnings surprises historically, yet faces near-term headwinds with negative profit margins, declining EPS Q/Q, and weak revenue growth. Valuation metrics suggest premium pricing with a Forward P/E of 29.22 and Price/Sales of 3.13, while insider activity is bearish and analyst recommendation remains 'buy' with a $348 target. Despite solid balance sheet strength, profitability deterioration and lack of dividend or intrinsic value clarity limit upside conviction.
Key Strengths
Piotroski F-Score of 6 indicates stable financial health with no immediate distress signals
Exceptionally strong liquidity position with Current Ratio of 5.44 and Quick Ratio of 3.62
High gross margin of 52.36% reflects pricing power and efficient cost control in core operations
Consistent history of beating earnings estimates, with 3 out of last 4 quarters above expectations and average surprise of 36.31%
Low Debt/Equity ratio of 0.21 suggests conservative capital structure and low leverage risk
Key Risks
Negative profit margin of -26.43% and negative ROE of -9.50% indicate current unprofitability and poor return on equity
Revenue growth of only 0.50% YoY signals stagnation in top-line expansion
Most recent Q/Q EPS growth declined by 13.4%, showing near-term earnings deterioration
Insider selling activity (1 sale, $0.21M) over past 6 months reflects lack of confidence from management
Lack of Graham Number and Intrinsic Value data prevents reliable fair value estimation, increasing valuation uncertainty
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
55
Moderate
50
58
70
76
20
AI Verdict
Neutral with upside potential if profitability recovers
Key drivers: Stable Piotroski score and strong liquidity, Persistent earnings beat streak despite recent Q/Q decline, Premium valuation constrains margin of safety, Negative profitability metrics weigh on long-term sustainability, Analyst target implies 17.3% upside, but lacks consensus depth (only 5 analysts)
Confidence
75%
Value
50/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 1.19 is modest relative to sector average ROE distortion
- Forward P/E of 29.22 may be justifiable if growth rebounds
Watchpoints
- No Graham Number or Intrinsic Value available for value anchoring
- High Price/Sales ratio of 3.13 vs minimal revenue growth raises concern
- Negative earnings make P/E and PEG ratios unreliable
Future
58/100
Ref Growth rates
Positives
- Year-over-Year EPS growth of +12.4% shows underlying profitability resilience
- Analyst target price implies positive forward expectations
Watchpoints
- Q/Q EPS growth down -13.4%, indicating recent deceleration
- Revenue growth of only 0.50% YoY limits future earnings runway
- No forward guidance or growth estimates provided
Past
70/100
Ref Historical trends
Positives
- Strong earnings surprise history: average +36.31% over last 4 quarters
- 20 of last 25 quarters beat or met estimates, demonstrating reporting consistency
- Long-term track record of operational execution despite volatility
Watchpoints
- Recent quarters show declining EPS trend from highs in 2022–2023
- Profitability metrics have deteriorated significantly compared to prior years
Health
76/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 6/9 indicates stable financial condition
- Very strong liquidity with Current Ratio of 5.44 and Quick Ratio of 3.62
- Low Debt/Equity of 0.21 reduces solvency risk
Watchpoints
- No Altman Z-Score available limits distress risk analysis
- Negative ROE (-9.50%) and negative net income undermine capital efficiency
Dividend
20/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength score of 0/100 and no dividend yield
- Payout ratio is 0.00%, indicating no return to shareholders
- No history of dividend payments to assess reliability
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$296.57
Analyst Target
$348.0
Upside/Downside
+17.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BIO and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories, Inc.
Primary
|
-49.6% | -35.1% | -15.9% | +12.3% | -1.7% | -5.4% |
|
HALO
Halozyme Therapeutics, Inc.
Peer
|
+57.9% | +84.6% | +17.5% | +5.8% | +2.0% | +5.2% |
|
AVTR
Avantor, Inc.
Peer
|
-61.5% | -48.8% | -46.0% | -17.0% | +4.6% | -3.0% |
|
CYTK
Cytokinetics, Incorporated
Peer
|
+170.7% | +87.1% | +81.9% | +8.8% | +4.9% | -0.7% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-40.4% | -45.2% | -50.0% | -23.3% | +11.7% | +2.4% |
BIO
Bio-Rad Laboratories, Inc.
Primary
5Y
-49.6%
3Y
-35.1%
1Y
-15.9%
6M
+12.3%
1M
-1.7%
1W
-5.4%
HAL
Halozyme Therapeutics, Inc.
Peer
5Y
+57.9%
3Y
+84.6%
1Y
+17.5%
6M
+5.8%
1M
+2.0%
1W
+5.2%
AVT
Avantor, Inc.
Peer
5Y
-61.5%
3Y
-48.8%
1Y
-46.0%
6M
-17.0%
1M
+4.6%
1W
-3.0%
CYT
Cytokinetics, Incorporated
Peer
5Y
+170.7%
3Y
+87.1%
1Y
+81.9%
6M
+8.8%
1M
+4.9%
1W
-0.7%
MOH
Molina Healthcare, Inc.
Peer
5Y
-40.4%
3Y
-45.2%
1Y
-50.0%
6M
-23.3%
1M
+11.7%
1W
+2.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
29.22
PEG Ratio
N/A
P/B Ratio
1.19
P/S Ratio
3.13
EV/Revenue
3.12
EV/EBITDA
19.1
Market Cap
$8.0B
Profitability
Profit margins and return metrics
Profit Margin
-26.43%
Operating Margin
10.41%
Gross Margin
52.36%
ROE
-9.5%
ROA
1.57%
Growth
Revenue and earnings growth rates
Revenue Growth
+0.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.21
Low debt
Current Ratio
5.44
Strong
Quick Ratio
3.62
Excellent
Cash/Share
$52.59
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-12
$N/A
2025-10-29
$2.26
+17.0% surprise
2025-07-31
$2.61
+49.5% surprise
2025-05-01
$2.54
+42.5% surprise
Healthcare Sector Comparison
Comparing BIO against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-9.5%
This Stock
vs
-88.14%
Sector Avg
-89.2%
(Below Avg)
Profit Margin
-26.43%
This Stock
vs
-16.28%
Sector Avg
+62.3%
(Superior)
Debt to Equity
0.21
This Stock
vs
2.66
Sector Avg
-92.2%
(Less Debt)
Revenue Growth
0.5%
This Stock
vs
124.04%
Sector Avg
-99.6%
(Slower)
Current Ratio
5.44
This Stock
vs
4.47
Sector Avg
+21.6%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories, Inc.
|
NEUTRAL | $8.0B | - | -9.5% | -26.4% | $296.57 | |
|
HALO
Halozyme Therapeutics, Inc.
|
NEUTRAL | $8.03B | 26.49 | 153.6% | 22.7% | $67.82 | Compare |
|
AVTR
Avantor, Inc.
|
BEARISH | $8.05B | - | -1.5% | -1.2% | $11.8 | Compare |
|
CYTK
Cytokinetics, Incorporated
|
NEUTRAL | $8.06B | - | -% | -% | $65.48 | Compare |
|
MOH
Molina Healthcare, Inc.
|
BEARISH | $7.87B | 16.83 | 11.0% | 1.1% | $151.0 | Compare |
BIO
Bio-Rad...
NEUTRAL
Mkt Cap
$8.0B
P/E
-
ROE
-9.5%
Price
$296.57
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-06 | BARRY JAMES | Officer | Sale | 699 | $214,289 |
| 2025-10-24 | DIVINCENZO JONATHAN P | President | Stock Award | 1,869 | - |
| 2025-10-20 | EVRAN SEDAT | Officer | Stock Award | 1,044 | - |
| 2025-09-05 | ALLISON SCHWARTZ | Director | Stock Award | 92 | - |
| 2025-09-05 | COREY COLLEEN | Officer | Stock Award | 576 | - |
| 2025-09-05 | EVRAN SEDAT | Officer | Stock Award | 864 | - |
| 2025-09-05 | ENLOE COURTNEY C | General Counsel | Stock Award | 768 | - |
| 2025-09-05 | BARRY JAMES | Officer | Stock Award | 1,056 | - |
| 2025-09-05 | ENGELHARDT EVA ANETTE | President | Stock Award | 1,152 | - |
| 2025-09-05 | SCHWARTZ NORMAN D | Chief Executive Officer | Stock Award | 3,455 | - |
| 2025-09-05 | LAKKARAJU ROOP KALYAN | Chief Financial Officer | Stock Award | 1,535 | - |
| 2025-08-29 | SCHWARTZ NORMAN D | Chief Executive Officer | Stock Award | 6,353 | - |
| 2025-08-29 | ALLISON SCHWARTZ | Director | Stock Award | 147 | - |
| 2025-08-29 | COREY COLLEEN | Officer | Stock Award | 1,102 | - |
| 2025-08-29 | BARRY JAMES | Officer | Stock Award | 602 | - |
BARRY JAMES
Officer
2025-11-06
699 shares
·
$214,289
DIVINCENZO JONATHAN P
President
2025-10-24
1,869 shares
EVRAN SEDAT
Officer
2025-10-20
1,044 shares
ALLISON SCHWARTZ
Director
2025-09-05
92 shares
COREY COLLEEN
Officer
2025-09-05
576 shares
EVRAN SEDAT
Officer
2025-09-05
864 shares
ENLOE COURTNEY C
General Counsel
2025-09-05
768 shares
BARRY JAMES
Officer
2025-09-05
1,056 shares
ENGELHARDT EVA ANETTE
President
2025-09-05
1,152 shares
SCHWARTZ NORMAN D
Chief Executive Officer
2025-09-05
3,455 shares
LAKKARAJU ROOP KALYAN
Chief Financial Officer
2025-09-05
1,535 shares
SCHWARTZ NORMAN D
Chief Executive Officer
2025-08-29
6,353 shares
ALLISON SCHWARTZ
Director
2025-08-29
147 shares
COREY COLLEEN
Officer
2025-08-29
1,102 shares
BARRY JAMES
Officer
2025-08-29
602 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
5 analysts
Citigroup
2025-10-30
Buy
Buy
Wells Fargo
2025-10-30
Equal-Weight
Equal-Weight
RBC Capital
2025-08-01
Outperform
Outperform
Wells Fargo
2025-08-01
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning BIO from our newsroom.
Newest → oldest
No matching news yet.